UMN's novel flu vaccine positive in early trial
This article was originally published in Scrip
Executive Summary
The Japanese venture UMN Pharmahas reported positive results from a Phase I/II trial with its novel pandemic flu vaccine UMN-0501. The company said responses had been observed in the low dose trial in 125 healthy male subjects, including with a non-aluminum adjuvant formulation, with no serious adverse reactions. It is now planning a larger Phase II trial at higher doses this year. The recombinant vaccine is manufactured using a baculovirus expression vector system and cultured insect cells to express the target haemagglutinin protein. This enables production times to be cut to around eight weeks, from six months or so for traditional egg-based methods (Scrip Online, June 11th, 2008). UMN-0501 already has orphan status in Japan.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.